Articles & insights to keep you updated on our latest developments
Stay up-to-date with our latest platform developments.
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Recent Posts
Audit Readiness for Infusion & SP: Documentation That Survives Payer Reviews
Jul 28, 2025
Units, Modifiers, and MUE Pitfalls: Coding Essentials for Infusion Services
Jul 28, 2025
Buy‑and‑Bill Denial Prevention: Top 10 Root Causes and How to Fix Them
Jul 28, 2025
Vial Optimization & JW Modifier: Cut Drug Waste and Denials
Jul 28, 2025
NDC‑to‑HCPCS Crosswalk Guide: Avoid J‑Code Errors on Infusion Claims
Jul 28, 2025
Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now
Jul 11, 2025
Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order
Jul 11, 2025
Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend
Jul 11, 2025
Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
Jul 10, 2025